ARISTO — Aristo Bio-Tech and Lifescience Cashflow Statement
0.000.00%
- IN₹607.94m
- IN₹935.66m
- IN₹3.64bn
Annual cashflow statement for Aristo Bio-Tech and Lifescience, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 20.4 | 47.4 | 54.1 | 54.7 | 97 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 26.8 | 27 | 16.5 | 16 | 37.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 9.99 | -118 | -10.3 | 3.47 | -75.7 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 68.2 | -27.8 | 76 | 100 | 88.5 |
| Capital Expenditures | -32.5 | -40.6 | -65.5 | -51.1 | -29.6 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.627 | 3.15 | -0.547 | -0.403 | -0.088 |
| Sale of Fixed Assets | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -31.9 | -37.5 | -66.1 | -51.5 | -29.7 |
| Financing Cash Flow Items | -23.6 | -41.6 | -15.9 | -16.9 | -39.5 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -33.3 | 79.7 | -22.1 | -43.9 | -43.7 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.04 | 14.4 | -12.2 | 4.78 | 15.1 |